Phase 3
Completed N=104
D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia
Source: ClinicalTrials.gov NCT00237809 ↗Enrolled (actual)
104
Serious AEs
0.0%
Results posted
May 2017
Primary outcomePrimary: Wisconsin Card Sorting Test (WCST) — 38.43; 35.79; 43.14; 39.57 percentage of correct responses
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
This study is based on the hypothesis that by increasing N-methyl-D-aspartic acid (NMDA) receptor function in the brain and thereby increasing the capacity of the brain to both form new connections and strengthen existing connections, schizophrenic patients may derive both greater and sustained benefit from cognitive retraining.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Wisconsin Card Sorting Test (WCST) |
38.43; 35.79; 43.14; 39.57 | — |
| PRIMARY Hopkins Verbal Learning Test |
20.74; 19.80; 20.42; 21.45 | — |
| PRIMARY Spatial Span- Total Score |
13.59; 13.88; 13.21; 13.58 | — |
| PRIMARY Positive and Negative Syndrome Scale (PANSS) |
53.30; 52.01; 53.79; 53.96 | — |
| SECONDARY Heinrichs-Carpenter Quality of Life Scale |
67.26; 68.30; 63.25; 63.92 | — |
| SECONDARY Simpson-Angus Neurological Rating Scale |
1.41; 0.72; 1.04; 1.81 | — |
| SECONDARY UCSD Performance-Based Skills Assessment (UPSA) |
34.19; 32.80; 32.60; 31.39 | — |
Eligibility Criteria
Inclusion Criteria
- Diagnosis of schizophrenia or schizoaffective disorder
Exclusion
- Pregnant or lactating
Data sourced from ClinicalTrials.gov (NCT00237809). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.